Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer
Hisato Kawakami(Tohoku University), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Masatoshi Kudo(Kindai University), Ken Kamata(Kindai University), Hidetoshi Hayashi(Kindai University), Koji Haratani(Dana-Farber Cancer Institute), Junko Tanizaki(Kindai University Sakai Hospital), Akihiko Ito(Kobe University), Mamoru Takenaka(Kindai University), Masayuki Takeda(Kindai University), Takao Sato(Kindai University Hospital), Kaoru Tanaka(Kindai University), Takaaki Chikugo(Kindai University), Masatomo Kimura(Kindai University)
Cited by 170
Related Papers
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
|Journal of Clinical Oncology|2011|1.6k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k